Michael Barbella, Managing Editor11.20.23
Halma has spent $90 million to purchase TeDan and expand both its technological expertise and its capabilities.
TeDan is a group of companies headquartered in Houston and Half Moon Bay, Calif., that develop, manufacture, and supply medical devices for use in spinal, neurological, cardiac and orthopedic procedures. The companies include TeDan Surgical Innovations Inc.; West Coast Surgical LLC; Axcess Surgical Innovations LLC; and TeDan Surgical Innovations GmbH.
“World spending on healthcare is increasing as demand continues to grow, especially as the number of people over 60 has reached more than one billion,” TeDan CEO Danny Fishman said. "For over 10 years, TeDan has been at the forefront of surgical access innovation, creating an improved experience for surgeons in the operating room and better outcomes for patients. Joining Halma will help us to grow and invest in the U.S. and internationally. Together, we share a common purpose of ensuring a healthier future for everyone, every day.”
The initial cash consideration for TeDan is $89.1 milliom (approximately £72 million), on a cash- and debt-free basis, which will be funded from Halma’s existing facilities. When adjusted for tax benefits with a net present value of roughly $9.8 million (approximately £8 million), the net initial consideration is about $79.3 million (approximately £64 million). An additional earn-out consideration of up to $10.9 million (approximately £9 million) is payable in cash, based on TeDan’s performance in the period to June 2024.
TeDan’s consolidated unaudited revenue for the 12 months ending March 31, 2023, was $29.2 million (approximately £24 million), and TeDan has a return on sales above the upper end of Halma's 18%-22% target range. TeDan will be a standalone company in Halma’s Healthcare sector, led by its current management team.
“TeDan further extends the technologies and capabilities of our Healthcare sector in the treatment of patients in acute therapeutic settings,” Halma Group CEO Marc Ronchetti stated. “TeDan’s growth is supported by the growing need for surgical treatment as populations age and as lifestyles evolve and by the development of innovative new surgical procedures which improve efficiency and standards of care. We are delighted to welcome the TeDan team to Halma and look forward to working with them to expand their global impact.”
The acquisition is part of Halma’s growth strategy to acquire bolt-on and standalone businesses, with a total of six acquisitions so far this financial year.
Halma is a global group of life-saving technology companies that operates in three markets—safety, environment, and health. It employs more than 8,000 people in over 20 countries, with major operations in the United Kingdom, mainland Europe, the United States, and Asia Pacific. Halma is listed on the London Stock Exchange and is a constituent of the FTSE 100 index.
TeDan is a group of companies headquartered in Houston and Half Moon Bay, Calif., that develop, manufacture, and supply medical devices for use in spinal, neurological, cardiac and orthopedic procedures. The companies include TeDan Surgical Innovations Inc.; West Coast Surgical LLC; Axcess Surgical Innovations LLC; and TeDan Surgical Innovations GmbH.
“World spending on healthcare is increasing as demand continues to grow, especially as the number of people over 60 has reached more than one billion,” TeDan CEO Danny Fishman said. "For over 10 years, TeDan has been at the forefront of surgical access innovation, creating an improved experience for surgeons in the operating room and better outcomes for patients. Joining Halma will help us to grow and invest in the U.S. and internationally. Together, we share a common purpose of ensuring a healthier future for everyone, every day.”
The initial cash consideration for TeDan is $89.1 milliom (approximately £72 million), on a cash- and debt-free basis, which will be funded from Halma’s existing facilities. When adjusted for tax benefits with a net present value of roughly $9.8 million (approximately £8 million), the net initial consideration is about $79.3 million (approximately £64 million). An additional earn-out consideration of up to $10.9 million (approximately £9 million) is payable in cash, based on TeDan’s performance in the period to June 2024.
TeDan’s consolidated unaudited revenue for the 12 months ending March 31, 2023, was $29.2 million (approximately £24 million), and TeDan has a return on sales above the upper end of Halma's 18%-22% target range. TeDan will be a standalone company in Halma’s Healthcare sector, led by its current management team.
“TeDan further extends the technologies and capabilities of our Healthcare sector in the treatment of patients in acute therapeutic settings,” Halma Group CEO Marc Ronchetti stated. “TeDan’s growth is supported by the growing need for surgical treatment as populations age and as lifestyles evolve and by the development of innovative new surgical procedures which improve efficiency and standards of care. We are delighted to welcome the TeDan team to Halma and look forward to working with them to expand their global impact.”
The acquisition is part of Halma’s growth strategy to acquire bolt-on and standalone businesses, with a total of six acquisitions so far this financial year.
Halma is a global group of life-saving technology companies that operates in three markets—safety, environment, and health. It employs more than 8,000 people in over 20 countries, with major operations in the United Kingdom, mainland Europe, the United States, and Asia Pacific. Halma is listed on the London Stock Exchange and is a constituent of the FTSE 100 index.